No survival benefit in follicular lymphoma with first-line intensive chemoimmunotherapy
This article has no abstract so we have provided the first paragraph of the full text.
Although intensive chemoimmunotherapy regimens with autologous stem-cell transplantation improve survival in patients with follicular lymphoma who have relapsed, the efficacy of this therapy as a first-line treatment is less clear. Recent studies, however, have indicated that combining high-dose regimens with rituximab might prove effective in initial treatment.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.